Mosapramine

Revision as of 13:56, 13 April 2015 by Turky Alkathery (talk | contribs) (Created page with "{{Drugbox | verifiedrevid = 444061994 | IUPAC_name = 1'-[3-(3-chloro-10,11-dihydro-5''H''-dibenzo[''b'',''f'']azepin-5-yl)propyl]hexahydro-2''H''-spiro[imidazo[1,2-''a'']pyrid...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Mosapramine
File:Mosapramine strucutre.svg
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC28H35ClN4O
Molar mass479.057 g/mol
3D model (JSmol)
  (verify)

Mosapramine (Cremin) is an atypical antipsychotic used in Japan.[1] It is a potent dopamine antagonist with high affinity to the D2, D3, and D4 receptors,[2] and with moderate affinity for the 5-HT2 receptors.[3]

See also

References

  1. Takahashi N, Terao T, Oga T, Okada M. Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. Neuropsychobiology. 1999;39(2):81-5. PMID 10072664
  2. Futamura T, Ohashi Y, Yano K, Takahashi Y, Haga K, Fukuda T. The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors. Nippon Yakurigaku Zasshi. (Japanese) 1996 May;107(5):247-53. PMID 8690306
  3. Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Mori H, Shiba K, Yokogawa K. Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy. Neuropsychopharmacology. 1995 Feb;12(1):57-64. doi:10.1016/0893-133X(94)00064-7 PMID 7766287

Template:Tricyclics


Template:Nervous-system-drug-stub